What are the latest figures on the prenatal testing & newborn screening market’s size and projected CAGR?
The prenatal testing & newborn screening market size has grown rapidly in recent years. It will grow from $6.24 billion in 2024 to $6.99 billion in 2025 at a compound annual growth rate (CAGR) of 12.0%. The growth in the historic period can be attributed to advancements in genetic testing, increased maternal age, awareness and education, healthcare policy and regulations.
The prenatal testing & newborn screening market size is expected to see rapid growth in the next few years. It will grow to $11.08 billion in 2029 at a compound annual growth rate (CAGR) of 12.2%. The growth in the forecast period can be attributed to genetic counseling, technological advancements, point-of-care testing, telehealth and remote monitoring. Major trends in the forecast period include non-invasive prenatal testing (nipt), preimplantation genetic testing (pgt), telemedicine consultations, maternal blood testing, hemoglobinopathies and sickle cell screening.
Get Your Free Sample of The Global Prenatal Testing & Newborn Screening Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3350&type=smp
Which Market drivers have played a significant role in driving the prenatal testing & newborn screening market?
The high prevalence of genetic diseases in infants contributed to the growth of the prenatal testing & newborn screening market. According to the World Health Organization, genetic disease includes diseases such as Thalassemia, Sickle Cell Anemia, Hemophilia, Cystic Fibrosis, Tay Sachs disease, Fragile X Syndrome, Huntington’s disease. The sickle cell anemia is one of the genetic diseases that affects millions throughout the world, and the disease is particularly common among people whose ancestors are from Africa, America, Cuba, Central America, Saudi Arabia, and India. For instance, in February 2023, according to the Rady Children’s Institute for Genomic Medicine, a US-based research institute, in a study conducted at Rady Children’s Hospital, 41% of infant deaths were attributed to single-locus (Mendelian) genetic diseases. The high prevalence of genetic diseases in infants boosted the demand for growth of the prenatal testing and newborn screening market.
What are the key segments within the prenatal testing & newborn screening market?
The prenatal testing & newborn screening market covered in this report is segmented –
1) By Diagnostic Type: Non-Invasive, Invasive
2) By Technology: Screening Technology, Diagnostic Technology
3) By End user: Hospitals, Diagnostic centers
Subsegments:
1) By Non-Invasive: Blood Tests (Cell-Free DNA Testing), Ultrasound, Maternal Serum Screening
2) By Invasive: Amniocentesis, Chorionic Villus Sampling (CVS), Cordocentesis
Order your report now for swift delivery
Which key players are shaping the prenatal testing & newborn screening market?
Major companies operating in the prenatal testing & newborn screening market include PerkinElmer Inc., Laboratory Corporation of America Holdings (LabCorp), Natera Inc., Invitae Corporation, Centogene AG, Cradle Genomics Inc., Roche Diagnostics International AG, Quest Diagnostics Incorporated, Baebies Inc., Progenity Inc., Ravgen Inc., Strand Life Sciences Pvt. Ltd., Eurofins Scientific, Illumina Inc., Agilent Technologies Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories Inc., General Electric Company, Siemens Healthineers AG, BGI Group, QIAGEN N.V., Veracyte Inc., NIPD Genetics, Novacyt UK, Ariosa Diagnostics Inc., Verinata Health Inc., Counsyl a Myriad Company, GenPath Diagnostics, Sonic Healthcare Limited, Cepheid a Danaher Company, Guardant Health Inc., Genetron Health (Beijing) Co. Ltd.
How will industry trends affect the trajectory of the prenatal testing & newborn screening market?
Major companies operating in the prenatal testing & newborn screening market focus on introducing novel programs that utilize rWGS (rapid Whole Genome Sequencing) technology to quickly and accurately detect genetic disorders in newborns, enabling early diagnosis and intervention to improve health outcomes. rWGS (rapid Whole Genome Sequencing) technology refers to an advanced genomic technique that rapidly sequences the entire genome of an individual. Unlike traditional genetic testing methods, which focus on specific genes or regions, rWGS captures all of the DNA in an individual’s genome to identify genetic variants associated with diseases or disorders. For instance, in June 2022, Rady Children’s Institute for Genomic Medicine, a US-based company, launched BeginNGS, a novel program. This initiative is designed to identify and diagnose approximately 400 genetic disorders that have known treatment options before symptoms manifest. BeginNGS is optimizing genomic sequencing processes with plans to expand testing capabilities to cover around 1,000 disorders. The ultimate goal is to enable screening for 3.7 million newborns annually, making it a standard practice in hospitals nationwide.
Which geographic trends are shaping the prenatal testing & newborn screening market, and which region has the highest market share?
North America was the largest region in the prenatal testing & newborn screening market in 2023. Western Europe was the second largest region in the prenatal testing and newborn screening market. The regions covered in the prenatal testing & newborn screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Does The Prenatal Testing & Newborn Screening Market Report 2025 Offer?
The prenatal testing & newborn screening market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Prenatal testing and newborn screening refer to the combined medical practices aimed at assessing the health of both the fetus during pregnancy and the newborn after birth. Prenatal testing includes various assessments, such as blood tests and ultrasounds, to identify potential genetic or developmental disorders in the fetus. Newborn screening involves conducting tests shortly after birth to detect metabolic, genetic, and endocrine disorders, allowing for early intervention and treatment to improve health outcomes for infants.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3350
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
